Liminatus Pharma, Inc. Class A Common Stock
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Chris Kim
- Full Time Employees
- 3
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 6 Centerpointe Drive La Palma CA United States of America 90623
- IPO Date
- May 1, 2025
- CIK
- 0001971387
- Website
- liminatuspharma.com
- Similar Companies
- Business
- Liminatus Pharma, Inc. is a pre-clinical-stage biopharmaceutical company focused on developing novel immune-modulating cancer therapies, including its lead candidate IBA101, a humanized anti-CD47 monoclonal antibody with IgG4 Fc designed to block the CD47-SIRPα interaction, promote macrophage-mediated phagocytosis of tumor cells, and target advanced solid tumors such as non-small cell lung cancer while minimizing anemia and thrombocytopenia risks associated with first-generation CD47 inhibitors; a high-affinity humanized anti-CD47 antibody aimed at restoring innate immune cell anti-tumor function without inducing hemagglutination or hemolysis; chimeric antigen receptor (CAR)-T cell therapies; and a Guanylyl Cyclase C (GCC) cancer vaccine in Phase II for metastatic colorectal, pancreatic, gastric, and esophageal cancers expressing GCC. Founded in 2018 and headquartered at 6 Centerpointe Drive, Suite 625, La Palma, California, the company operates in the immuno-oncology segment of the biotechnology industry, targeting patients with solid tumors through therapies originating from collaborations with Thomas Jefferson University and South Korea's Innobation Bio. In October 2025, Liminatus entered a Memorandum of Understanding with New Zealand-based Capital Trust Group Limited for up to $30 million in equity financing via an earn-out mechanism to advance its research and development programs, including next-generation CD47-blockade therapies, with definitive agreements targeted for November 2025 and potential future digital bond financing discussions.
Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds
Liminatus Pharma Announces Nasdaq Delisting Notification
Liminatus Pharma Announces Nasdaq Delisting Notification
Liminatus Pharma Is Trending Overnight — Here's Why LIMN Stock Surged Over 79% In After-Hours Session
Athira Pharma (NASDAQ:LONA) and Liminatus Pharma (NASDAQ:LIMN) Head to Head Analysis
Reviewing Athira Pharma (NASDAQ:LONA) & Liminatus Pharma (NASDAQ:LIMN)
Liminatus Pharma Announces Planned Phase 1 Clinical Trial of IBA101, a Next-Generation CD47 Blocking Antibody
Financial Contrast: Athira Pharma (NASDAQ:LONA) and Liminatus Pharma (NASDAQ:LIMN)
Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering
Comparing Liminatus Pharma (NASDAQ:LIMN) & Inhibikase Therapeutics (NASDAQ:IKT)
Liminatus Pharma (NASDAQ:LIMN) vs. Inhibikase Therapeutics (NASDAQ:IKT) Head-To-Head Contrast
Liminatus Pharma (NASDAQ:LIMN) and Inhibikase Therapeutics (NASDAQ:IKT) Head-To-Head Survey
Critical Survey: Inhibikase Therapeutics (NASDAQ:IKT) versus Liminatus Pharma (NASDAQ:LIMN)
Analyzing Liminatus Pharma (NASDAQ:LIMN) and Inhibikase Therapeutics (NASDAQ:IKT)
Financial Analysis: Inhibikase Therapeutics (NASDAQ:IKT) and Liminatus Pharma (NASDAQ:LIMN)
Reviewing Vor Biopharma (NASDAQ:VOR) and Liminatus Pharma (NASDAQ:LIMN)
Liminatus Pharma (NASDAQ:LIMN) versus Prime Medicine (NASDAQ:PRME) Head to Head Comparison
Analyzing Prime Medicine (NASDAQ:PRME) and Liminatus Pharma (NASDAQ:LIMN)
Head to Head Analysis: Liminatus Pharma (NASDAQ:LIMN) versus Vor Biopharma (NASDAQ:VOR)
Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation